At #IMS24, data from our robust portfolio of complementary and combinable #MultipleMyeloma treatments demonstrate how we are constantly innovating in the effort to improve outcomes for patients across all lines of therapy: t.co/IhnnCyMa6B #JNJOncology t.co/OlDxULzitC